Search research articles
Contact Us
Filters
Showing results (81-90 of 128) with videos related to
Page
of 13
Sort By:
Hybridoma
|
December 1, 1996
Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens
K P O'Boyle, A L Markowitz, M Khorshidi, et al.
The Journal of Infectious Diseases
|
March 23, 2001
Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis
K V Komanduri, J Feinberg, R K Hutchins, et al.
Transplantation Proceedings
|
March 1, 1973
Recognition and treatment of rejection in experimental and human lung allografts
F J Veith, S K Koerner, S S Siegelman, et al.
AIDS (London, England)
|
March 17, 2023
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
Felicia L Sterman, Jacob P Lalezari, Ula M Kowalczyk, et al.
The Journal of Infectious Diseases
|
September 1, 1994
Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS
J P Lalezari, W L Drew, E Glutzer, et al.
The Journal of Infectious Diseases
|
April 1, 1995
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue
J P Lalezari, W L Drew, E Glutzer, et al.
Antimicrobial Agents and Chemotherapy
|
October 1, 1995
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling
G J Yuen, G L Drusano, C Fletcher, et al.
The Journal of Infectious Diseases
|
June 1, 1995
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group
S A Spector, D F Busch, S Follansbee, et al.
The Journal of Infectious Diseases
|
April 9, 2026
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load
Tanaya R Vaidya, Till Geib, Jacob P Lalezari, et al.
Blood
|
May 15, 1993
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia
D C Dale, M A Bonilla, M W Davis, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 128) with videos related to
Sort By:
Page
of 13
Hybridoma
|
December 1, 1996
Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens
K P O'Boyle, A L Markowitz, M Khorshidi, et al.
The Journal of Infectious Diseases
|
March 23, 2001
Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis
K V Komanduri, J Feinberg, R K Hutchins, et al.
Transplantation Proceedings
|
March 1, 1973
Recognition and treatment of rejection in experimental and human lung allografts
F J Veith, S K Koerner, S S Siegelman, et al.
AIDS (London, England)
|
March 17, 2023
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
Felicia L Sterman, Jacob P Lalezari, Ula M Kowalczyk, et al.
The Journal of Infectious Diseases
|
September 1, 1994
Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS
J P Lalezari, W L Drew, E Glutzer, et al.
The Journal of Infectious Diseases
|
April 1, 1995
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue
J P Lalezari, W L Drew, E Glutzer, et al.
Antimicrobial Agents and Chemotherapy
|
October 1, 1995
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling
G J Yuen, G L Drusano, C Fletcher, et al.
The Journal of Infectious Diseases
|
June 1, 1995
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group
S A Spector, D F Busch, S Follansbee, et al.
The Journal of Infectious Diseases
|
April 9, 2026
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load
Tanaya R Vaidya, Till Geib, Jacob P Lalezari, et al.
Blood
|
May 15, 1993
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia
D C Dale, M A Bonilla, M W Davis, et al.
Page
of 13